Vinva Investment Management LTD Neurocrine Biosciences Inc Transaction History

Vinva Investment Management LTD

$3.85 Trillion
Q2 2025

A detailed history of Vinva Investment Management LTD transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Vinva Investment Management LTD holds 5,085 shares of NBIX stock, worth $725,375. This represents 0.02% of its overall portfolio holdings.

Number of Shares

5,085

Previous 4,749 7.08%

Holding current value

$725,375

Previous $537 Million 18.68%

% of portfolio

0.02%

Previous 0.02%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 12, 2025	BUY	$87.54 - $128.18 $29,413 - $43,068	336 Added 7.08%	5,085 $638 Million
Q1 2025 May 13, 2025	SELL	$107.22 - $153.29 $915,873 - $1.31 Million	-8,542 Reduced 64.27%	4,749 $537 Million
Q4 2024 Feb 10, 2025	SELL	$111.62 - $139.44 $2.82 Million - $3.52 Million	-25,249 Reduced 65.51%	13,291 $1.82 Billion
Q3 2024 Nov 13, 2024	BUY	$114.58 - $153.15 $2.5 Million - $3.34 Million	21,795 Added 130.16%	38,540 $4.43 Billion
Q2 2024 Aug 13, 2024	BUY	$130.86 - $143.19 $1.34 Million - $1.47 Million	10,266 Added 158.45%	16,745 $2.25 Billion
Q1 2024 May 13, 2024	BUY	$130.4 - $143.74 $218,811 - $241,195	1,678 Added 34.95%	6,479 $894 Million
Q4 2023 Feb 13, 2024	BUY	$106.07 - $132.76 $68,945 - $86,294	650 Added 15.66%	4,801 $634 Million
Q3 2023 Nov 13, 2023	SELL	$94.02 - $117.1 $99,943 - $124,477	-1,063 Reduced 20.39%	4,151 $478 Million
Q2 2023 Aug 14, 2023	SELL	$89.53 - $104.87 $825,018 - $966,377	-9,215 Reduced 63.86%	5,214 $493 Million
Q1 2023 May 11, 2023	BUY	$94.11 - $123.02 $1.36 Million - $1.78 Million	14,429 New	14,429 $1.43 Billion

Others Institutions Holding NBIX

# of Institutions

662

Shares Held

102M

Call Options Held

290K

Put Options Held

214K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13.6B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vinva Investment Management LTD, based on Form 13F filings with the SEC.

News

Stay updated on Vinva Investment Management LTD with notifications on news.

Account

Vinva Investment Management LTD Neurocrine Biosciences Inc Transaction History